This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The base case used assumptions about health outcomes based on randomised trials. A base case hospital (fully covered lab scenario) was defined as having an existing cardiac catheterisation lab that performed elective procedures during weekdays and had cardiovascular surgical backup. Seven cardiologists reviewed the evidence tables that summarised the published reports about each assumption. To derive each final base case estimate, a modified Delphi approach was used in which each panellist submitted initial estimates, then reviewed and adjusted results to reach as much consensus as possible.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
38 studies were considered.
Methods of combining primary studies
A modified Delphi approach.
Investigation of differences between primary studies
Results of the review
Base case estimates for in-hospital mortality among patient sub-groups varied between 0.04 and 0.85, among thrombolysis candidates the range was 0.002 -0.93, procedure rates (CABG, angioplasty during hospital stay, angioplasty during next year) were in the range 0.04 to 0.30.
Methods used to derive estimates of effectiveness
Estimates of effectiveness were also derived from an expert panel.
Estimates of effectiveness and key assumptions
Bleeding requiring transfusion: 0.03 for primary angioplasty, 0.02 for thrombolysis and 0.005 for no intervention.
Measure of benefits used in the economic analysis
Life-years saved and quality-adjusted life years (QALYs) saved were calculated. Quality of life adjustments were made using utilities from published patient preference studies.
HMO as well as experts-opinion was used in estimating the costs of hospital stay. The annual average costs of medical care were estimated based on the National Medical Expenditure Survey and the Coronary Heart Disease Policy Model. As stated by the authors, direct medical costs from a societal perspective were considered. 1993 costs were used and costs from other years were adjusted to 1993 dollars using the medical component of the Consumer Price Index. Costs were discounted at 3% per year over a period of 10 years.
Statistical analysis of costs
Not performed.
Currency

US dollars ($).
Sensitivity analysis
The authors varied four major factors both individually and simultaneously, as follows: (1) the effectiveness of primary angioplasty; (2) the hospital scenarios in which it might be offered; (3) the volume of services; (4) the time to treatment. Sensitivity analyses were also conducted for individual assumptions including in-hospital mortality, long-term survival, subsequent cardiac quality of life, the cost of thrombolysis, the cost of future medical care for survivors and the discount rate.
Estimated benefits used in the economic analysis
Life-years saved were found to be 684 and 741 QALYs were saved with primary angioplasty.
Cost results
Total costs (10,000 patients) for primary angioplasty were $724 million, for thrombolysis were $726 million, and for no intervention were $690 million.
Synthesis of costs and benefits
Under the base case scenario, primary angioplasty resulted in cost savings compared with thrombolysis and had a cost of $12,000/QALY saved compared to no intervention. In sensitivity analyses, when there was an existing cardiac catheterisation lab at a hospital with more than 200 patients with MI annually, primary angioplasty had a cost of less than $30,000/QALY saved under a wide range of assumptions. However, the cost/QALY saved increased sharply under effectiveness assumptions when the hospital had fewer than 150 patients with MI annually or when a redundant lab was built.
